These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 29902579)
21. Expression of androgen receptors in primary breast cancer. Park S; Koo J; Park HS; Kim JH; Choi SY; Lee JH; Park BW; Lee KS Ann Oncol; 2010 Mar; 21(3):488-492. PubMed ID: 19887463 [TBL] [Abstract][Full Text] [Related]
22. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Choi J; Jung WH; Koo JS Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247 [TBL] [Abstract][Full Text] [Related]
23. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. He J; Peng R; Yuan Z; Wang S; Peng J; Lin G; Jiang X; Qin T Med Oncol; 2012 Jun; 29(2):406-10. PubMed ID: 21264529 [TBL] [Abstract][Full Text] [Related]
24. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Tsutsumi Y Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930 [TBL] [Abstract][Full Text] [Related]
25. Association between androgen receptor status and prognosis in triple negative breast cancer. Sunar V; T Dogan H; Sarici F; Ates O; Akin S; Baspinar B; Aksoy S; Altundag K J BUON; 2018; 23(5):1325-1330. PubMed ID: 30570854 [TBL] [Abstract][Full Text] [Related]
26. Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival. Kalvala J; Parks RM; Abdi J; Green AR; Cheung KL Adv Ther; 2023 Jun; 40(6):2820-2835. PubMed ID: 37118159 [TBL] [Abstract][Full Text] [Related]
27. Expression of androgen receptors in triple negative breast carcinomas. Mrklić I; Pogorelić Z; Capkun V; Tomić S Acta Histochem; 2013 May; 115(4):344-8. PubMed ID: 23031358 [TBL] [Abstract][Full Text] [Related]
28. Prognostic markers in triple-negative breast cancer. Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782 [TBL] [Abstract][Full Text] [Related]
29. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Tozbikian GH; Zynger DL Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800 [TBL] [Abstract][Full Text] [Related]
30. Imaging features of triple-negative breast cancers according to androgen receptor status. Candelaria RP; Adrada BE; Wei W; Thompson AM; Santiago L; Lane DL; Huang ML; Arribas EM; Rauch GM; Symmans WF; Gilcrease MZ; Huo L; Lim B; Ueno NT; Moulder SL; Yang WT Eur J Radiol; 2019 May; 114():167-174. PubMed ID: 31005169 [TBL] [Abstract][Full Text] [Related]
31. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351 [TBL] [Abstract][Full Text] [Related]
32. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. Riaz N; Idress R; Habib S; Lalani EN Front Oncol; 2020; 10():1083. PubMed ID: 32850312 [No Abstract] [Full Text] [Related]
33. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases. Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563 [TBL] [Abstract][Full Text] [Related]
34. Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups. Niméus E; Folkesson E; Nodin B; Hartman L; Klintman M Anticancer Res; 2017 Dec; 37(12):6845-6853. PubMed ID: 29187464 [TBL] [Abstract][Full Text] [Related]
35. Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer. Hu XQ; Chen WL; Ma HG; Jiang K Oncotarget; 2017 Aug; 8(34):56364-56374. PubMed ID: 28915596 [TBL] [Abstract][Full Text] [Related]
36. Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients. Sable M; Pai TD; Shet T; Patil A; Dhanavade S; Desai SB Int J Surg Pathol; 2017 May; 25(3):230-237. PubMed ID: 27612858 [TBL] [Abstract][Full Text] [Related]
37. Tissue Microarray Immunohistochemical Staining for Androgen Receptor in Breast Cancer in a Ghanaian Cohort. Duduyemi BM; Ayibor WG; Agyemang-Yeboah F Ann Afr Med; 2024 Jul; 23(3):452-458. PubMed ID: 39034572 [TBL] [Abstract][Full Text] [Related]
38. Expression and clinical significance of androgen receptor in triple negative breast cancer. Luo X; Shi YX; Li ZM; Jiang WQ Chin J Cancer; 2010 Jun; 29(6):585-90. PubMed ID: 20507730 [TBL] [Abstract][Full Text] [Related]
39. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266 [TBL] [Abstract][Full Text] [Related]
40. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer? Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]